Aarkstore Enterprise--- Pharmaceutical Pricing, Reimbursement & Distribution In Poland, 2010 And B

Poland, the largest market in central and eastern Europe

, has weathered the global economic downturn better than many other countries across the continent. Its USD 6+ billion pharmaceutical sector (at ex-factory prices) in particular has been remarkably resilient, with value growth in each of the past three years exceeding 9%, the second highest increase in the EU. Traditionally a market dominated by generics, imported originator brands now account for 72% of sales Yet pricing and reimbursement processes are far from transparent, and if OTCs are included, patients are asked to pay 68% of the medicines bill out-of-pocket, a very high share for a country with a comprehensive social health insurance system.

Poland is full of surprises. Be better prepared and informed to tackle this dynamic emerging market. Pharmaceutical Pricing, Reimbursement & Distribution in Poland, 2010 and Beyond will provide you with clear, comprehensive, fully-researched and up-to-date information, including the following:

*

How introductory prices are set.

*

The complex forms of reimbursement explained with many illustrative examples.

*

Alternatives to appearing on the positive list.

*

How manufacturer discounts lessen the co-payment burden and drive market share.

*

Therapeutic programmes for high-cost speciality drugs.

*

Which products have maximum acquisition prices set for hospitals.

*

First 12 months experience with AstraZenecas direct-to-pharmacy distribution model, the only form of exclusive DTP in Europe outside the UK.

*

Two-way flow in one of Europes newest and fastest-growing parallel trade scenes.

*

Reforms to P&R the government is now proposing and what these might mean for the pharmaceutical industry.

Table of Contents :

Executive Summary

1. Market Introduction

1.1 Healthcare System

1.2 Health Insurance

1.2.1 Public System

1.2.2 Private System

1.3 Pharmaceutical Market

1.4 Pharmaceutical Industry

1.5 Regulation

2. Introductory Pricing

2.1 Principles

2.2 Process

2.2.1 Medicines Management Team

2.2.2 Agency for Medical Technology Evaluations

2.2.3 External Reference Pricing

2.2.4 Internal Reference Pricing

2.3 Outcome

2.4 Price Revision

For more information please contact :

http://www.aarkstore.com/reports/Pharmaceutical-Pricing-Reimbursement-Distribution-in-Poland-2010-and-Beyond-44733.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise

Contact: Neel

Email: press@aarkstore.com

URL: www.aarkstore.com

by: Aarkstore Enterprise

POST COMMENT

Aarkstore Enterprise--- Complete Guide To The 2009 Pprs, Nice & Other Pharmaceutical Cost Containm Aarkstore Enterprise--- Pharmacy Liberalisation In Europe: Prospects And Implications Sep 2008 Grupo Bimbo S.a.b. De C.v.: Corporate Analysis --- Aarkstore Enterprise Aarkstore Enterprise---pharmaceutical Pricing And Distribution In Japan: The Keys To Success In The Luxottica Group S.p.a.: Corporate Analysis --- Aarkstore Enterprise Fortune Brands, Inc.: Corporate Analysis --- Aarkstore Enterprise Tdc A/s: Corporate Analysis --- Aarkstore Enterprise Air China Ltd.: Corporate Analysis --- Aarkstore Enterprise Prysmian Spa Corporate Analysis --- Aarkstore Enterprise Kt Freetel Co Ltd Corporate Analysis --- Aarkstore Enterprise Telekomunikacja Polska Sa: Corporate Analysis --- Aarkstore Enterprise Ball Corporation: Corporate Analysis --- Aarkstore Enterprise Aarkstore Enterprise---oil And Gas Supply Demand Outlook In Europe And Former Soviet Union To 2020 -